Mosaic Immunoengineering Stock Performance

CPMV Stock  USD 0.53  0.22  70.97%   
Mosaic Immunoengineerin holds a performance score of 5 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 1.21, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Mosaic Immunoengineerin will likely underperform. Use Mosaic Immunoengineering jensen alpha, potential upside, as well as the relationship between the Potential Upside and daily balance of power , to analyze future returns on Mosaic Immunoengineering.

Risk-Adjusted Performance

Mild

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Mosaic Immunoengineering are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile primary indicators, Mosaic Immunoengineerin showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Begin Period Cash Flow352.7 K
Total Cashflows From Investing Activities27.6 K
  

Mosaic Immunoengineerin Relative Risk vs. Return Landscape

If you would invest  60.00  in Mosaic Immunoengineering on November 17, 2025 and sell it today you would lose (7.00) from holding Mosaic Immunoengineering or give up 11.67% of portfolio value over 90 days. Mosaic Immunoengineering is currently generating 1.4603% in daily expected returns and assumes 19.3696% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Mosaic, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Mosaic Immunoengineerin is expected to generate 25.35 times more return on investment than the market. However, the company is 25.35 times more volatile than its market benchmark. It trades about 0.08 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.13 per unit of risk.

Mosaic Immunoengineerin Target Price Odds to finish over Current Price

The tendency of Mosaic OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.53 90 days 0.53 
about 50.0
Based on a normal probability distribution, the odds of Mosaic Immunoengineerin to move above the current price in 90 days from now is about 50.0 (This Mosaic Immunoengineering probability density function shows the probability of Mosaic OTC Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the otc stock has the beta coefficient of 1.21 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Mosaic Immunoengineerin will likely underperform. Additionally Mosaic Immunoengineering has an alpha of 0.8193, implying that it can generate a 0.82 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Mosaic Immunoengineerin Price Density   
       Price  

Predictive Modules for Mosaic Immunoengineerin

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Mosaic Immunoengineering. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.030.5319.90
Details
Intrinsic
Valuation
LowRealHigh
0.020.4319.80
Details

Mosaic Immunoengineerin Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Mosaic Immunoengineerin is not an exception. The market had few large corrections towards the Mosaic Immunoengineerin's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Mosaic Immunoengineering, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Mosaic Immunoengineerin within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.82
β
Beta against Dow Jones1.21
σ
Overall volatility
0.13
Ir
Information ratio 0.04

Mosaic Immunoengineerin Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Mosaic Immunoengineerin for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Mosaic Immunoengineering can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Mosaic Immunoengineerin is way too risky over 90 days horizon
Mosaic Immunoengineerin has some characteristics of a very speculative penny stock
Mosaic Immunoengineerin appears to be risky and price may revert if volatility continues
Mosaic Immunoengineerin has high likelihood to experience some financial distress in the next 2 years
Mosaic Immunoengineering currently holds 735.15 K in liabilities. Mosaic Immunoengineering has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Mosaic Immunoengineerin until it has trouble settling it off, either with new capital or with free cash flow. So, Mosaic Immunoengineerin's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mosaic Immunoengineering sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mosaic to invest in growth at high rates of return. When we think about Mosaic Immunoengineerin's use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (3.68 M) with profit before overhead, payroll, taxes, and interest of 0.
Mosaic Immunoengineering currently holds about 205.99 K in cash with (679.24 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.03.
Roughly 89.0% of the company shares are held by company insiders

Mosaic Immunoengineerin Fundamentals Growth

Mosaic OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Mosaic Immunoengineerin, and Mosaic Immunoengineerin fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mosaic OTC Stock performance.

About Mosaic Immunoengineerin Performance

Evaluating Mosaic Immunoengineerin's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Mosaic Immunoengineerin has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Mosaic Immunoengineerin has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Mosaic ImmunoEngineering Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. The company was founded in 2020 and is based in Novato, California. Mosaic Immunoengineerin operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.

Things to note about Mosaic Immunoengineering performance evaluation

Checking the ongoing alerts about Mosaic Immunoengineerin for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Mosaic Immunoengineering help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Mosaic Immunoengineerin is way too risky over 90 days horizon
Mosaic Immunoengineerin has some characteristics of a very speculative penny stock
Mosaic Immunoengineerin appears to be risky and price may revert if volatility continues
Mosaic Immunoengineerin has high likelihood to experience some financial distress in the next 2 years
Mosaic Immunoengineering currently holds 735.15 K in liabilities. Mosaic Immunoengineering has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Mosaic Immunoengineerin until it has trouble settling it off, either with new capital or with free cash flow. So, Mosaic Immunoengineerin's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mosaic Immunoengineering sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mosaic to invest in growth at high rates of return. When we think about Mosaic Immunoengineerin's use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (3.68 M) with profit before overhead, payroll, taxes, and interest of 0.
Mosaic Immunoengineering currently holds about 205.99 K in cash with (679.24 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.03.
Roughly 89.0% of the company shares are held by company insiders
Evaluating Mosaic Immunoengineerin's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Mosaic Immunoengineerin's otc stock performance include:
  • Analyzing Mosaic Immunoengineerin's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mosaic Immunoengineerin's stock is overvalued or undervalued compared to its peers.
  • Examining Mosaic Immunoengineerin's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Mosaic Immunoengineerin's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mosaic Immunoengineerin's management team can help you assess the OTC Stock's leadership.
  • Pay attention to analyst opinions and ratings of Mosaic Immunoengineerin's otc stock. These opinions can provide insight into Mosaic Immunoengineerin's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Mosaic Immunoengineerin's otc stock performance is not an exact science, and many factors can impact Mosaic Immunoengineerin's otc stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Mosaic OTC Stock Analysis

When running Mosaic Immunoengineerin's price analysis, check to measure Mosaic Immunoengineerin's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mosaic Immunoengineerin is operating at the current time. Most of Mosaic Immunoengineerin's value examination focuses on studying past and present price action to predict the probability of Mosaic Immunoengineerin's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mosaic Immunoengineerin's price. Additionally, you may evaluate how the addition of Mosaic Immunoengineerin to your portfolios can decrease your overall portfolio volatility.